Compare Microchip Technology Inc. (MCHP) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Microchip Technology Inc. trades at $82.22 (market cap $43.99B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: Microchip Technology Inc. is far larger — about 24.3× Recursion Pharmaceuticals Inc's market cap, and Microchip Technology Inc. pays a 2.25% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| MCHP | RXRX | |
|---|---|---|
Market Cap | $43.99B | $1.81B |
Sector | Technology | Health |
52-Week High | $102.97 | $6.79 |
52-Week Low | $49.02 | $2.84 |
Enterprise Value | $49.12B | $1.33B |
Dividend Yield | 2.25% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
